Seeking Alpha

Amgen (AMGN) says Phase 2 studies of its investigational antibody AMG 145, in combination with...

Amgen (AMGN) says Phase 2 studies of its investigational antibody AMG 145, in combination with statin therapy, resulted in a 56% reduction in low density lipoprotein cholesterol, the "bad" cholesterol, in patients with heterozygous familial hypercholesterolemia. The study was published in Circulation and presented at the American Heart Association Scientific Sessions 2012.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs